Alvotech (ICE:ALVO)
Iceland · Delayed Price · Currency is ISK | Market Cap | 153.81B -62.8% |
| Revenue (ttm) | 69.97B -4.4% |
| Net Income | -10.05B |
| EPS | -34.39 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 26.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,258 |
| Open | 502.00 |
| Previous Close | 518.00 |
| Day's Range | 483.00 - 502.00 |
| 52-Week Range | 364.00 - 1,240.00 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat variou... [Read more]
News
Transactions of Managers and Closely Associated Persons
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition ...
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medi...
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of...
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medi...
Transactions of Managers and Closely Associated Persons
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the allocation ...
Alvotech Transcript: UBS Virtual Generics and Biosimilars Day
The company is positioned for significant growth with a robust biosimilar pipeline, strong global partnerships, and recent regulatory progress. Key launches for SIMPONI, EYLEA, and Entyvio are on track, supported by expanded manufacturing and a focus on limited-competition markets.
Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is at a pivotal stage, having addressed FDA facility concerns and resubmitted key BLAs, with multiple U.S. launches expected by year-end. Its pipeline targets high-value biosimilars like Entyvio and Eylea, supported by expanded manufacturing and a strategy to be first-to-market in major categories.
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pati...
Alvotech Transcript: Jefferies Global Healthcare Conference 2026
The company is accelerating U.S. launches with recent FDA resubmissions and expects five products on the U.S. market by year-end. Expanded manufacturing through a Fujifilm partnership supports a robust pipeline, with first-to-market ambitions for key biosimilars like ENTYVIO and high-dose Eylea. 2026 guidance projects strong revenue and EBITDA growth.
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pati...
Main Results of 2026 Annual and Extraordinary General Meeting
The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg.
Alvotech to present at upcoming investor conferences in June
REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar me...
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and ...
Alvotech Transcript: Bank of America Global Healthcare Conference 2026
Recent launches and a robust pipeline position the company for limited-competition biosimilar entries, with regulatory remediation on track for key approvals by year-end. Expanded manufacturing and strategic partnerships support growth, while industry consolidation and regulatory changes enhance competitive positioning.
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializi...
Alvotech Earnings Call Transcript: Q1 2026
Q1 2026 saw revenues decline 20% year-over-year to $106 million due to facility improvements, but gross margin improved and EBITDA margin rose to 23%. Regulatory progress, new launches, and a strategic FUJIFILM partnership position the company for strong growth in 2027.
Alvotech Earnings release: Q1 2026
Alvotech released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Alvotech Slides: Q1 2026
Alvotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Alvotech Q1 2026 Financial Results
Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational details and business update for Q1 202...
Alvotech Announces a Change in its Executive Team
REYKJAVIK, ICELAND (April 30, 2026) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Alvotech to Report Financial Results for the First Quarter of 2026
REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar m...
Alvotech files Annual Report with the SEC
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commissio...
Alvotech Publishes 2025 Annual Report
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the investor relations section of Alvotech's website...
Alvotech Earnings Call Transcript: Q4 2025
2025 saw 21% revenue growth to $593M and 27% higher adjusted EBITDA, driven by licensing and new launches. Guidance for 2026 is $650–$700M revenue, with U.S. launches providing upside. Regulatory remediation and expanded manufacturing underpin future growth.
Alvotech Annual report: Q4 2025
Alvotech has published its Q4 2025 annual report on March 19, 2026.